Sp377
BARRETT'S SURVEILLANCE: IS THERE ANYTHING REALLY BETER THAN THE SEATTLE PROTOCAL?
Date
May 7, 2023
Explore related products in the following collection:
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
STATE OF THE ART IN ENDOSCOIC ERADICATION THERAPY FOR BARRETT'S RELATED NEOPLASIA
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates…
INTRODUCTION
SOCIETY: AGA